天工國際(00826.HK)附屬訂粉末冶金分銷協議
天工國際(00826.HK)公布,間接全資附屬公司天工發展與歐洲特鋼產品領先供應商訂立粉末冶金獨家分銷協議。
根據協議,天工發展將向歐洲市場的業務夥伴獨家提供各種尺寸的粉末冶金鋼產品,而業務夥伴有權於歐洲市場銷售該等粉末冶金鋼產品。
協議項下總供應量分別為2021年7月1日至2022年6月30日為30至50噸;2022年7月1日至2023年6月30日為50至100噸;2023年7月1日至2024年6月30日為200至300噸;2024年7月1日至2025年6月30日為300至600噸。
公司指,協議將有助於確保對集團新冶金產品需求的穩定,並因此可提升集團粉末冶金生產線投資的盈利能力及回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.